March 06, 2015 9:42 AM ET

Biotechnology

Company Overview of Tokai Pharmaceuticals, Inc.

Company Overview

Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel proprietary therapies for the treatment of prostate cancer and other hormonally-driven diseases in the United States. Its lead drug candidate includes galeterone, an oral small molecule drug candidate, which is in Phase II clinical trials for the treatment of castration resistant prostate cancer. The company was founded in 2004 and is headquartered in Cambridge, Massachusetts.

One Broadway

14th Floor

Cambridge, MA 02142

United States

Founded in 2004

14 Employees

Phone:

617-225-4305

Key Executives for Tokai Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 39
Total Annual Compensation: $422.0K
Compensation as of Fiscal Year 2013.

Tokai Pharmaceuticals, Inc. Key Developments

Tokai Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 08:00 AM

Tokai Pharmaceuticals, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 08:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Jodie Pope Morrison, Chief Executive Officer, President and Director.

Tokai Pharmaceuticals Obtains Exclusive, Worldwide License from the Johns Hopkins University

Tokai Pharmaceuticals reported that it has entered into an agreement with the Johns Hopkins University related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Company's lead product, galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC. Under the agreement, the Company has obtained an exclusive, worldwide license from the Johns Hopkins University to patent applications and know-how covering an assay that has been used to determine the AR-V7 status of prostate cancer patients.

Tokai Pharmaceuticals, Inc. Appoints Stephen Buckley, Jr. to the Board of Directors and as Chair of the Audit Committee

Tokai Pharmaceuticals, Inc. announced that Stephen Buckley, Jr. has joined the company’s board of directors and will serve as chair of the audit committee. Mr. Buckley spent 25 years as a partner of Ernst & Young LLP, where he led assurance and advisory teams serving public and private companies in life sciences and other technologies. Mr. Buckley ran Ernst & Young’s Life Sciences Industry Practice of New England from 1991 to 2006, and was director of its New England Entrepreneurial Services Group from 1991 to 2001. He was previously a partner in the Boston, Massachusetts office of Arthur Young until its merger into Ernst & Young in 1989.

Similar Private Companies By Industry

Company Name Region
Myrmidon Biomaterials Inc. United States
Toma Biosciences, Inc. United States
Tetracore, Inc. United States
Tissue Engineering, Inc. United States
Phloronol, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Tokai Pharmaceuticals, Inc., please visit www.tokaipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.